New York State Teachers Retirement System Sells 1,538 Shares of United Therapeutics Corporation $UTHR

New York State Teachers Retirement System cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,334 shares of the biotechnology company’s stock after selling 1,538 shares during the quarter. New York State Teachers Retirement System owned about 0.11% of United Therapeutics worth $29,254,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Independent Advisor Alliance grew its position in shares of United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. NDVR Inc. boosted its stake in United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 30 shares in the last quarter. Principal Securities Inc. grew its holdings in United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 31 shares during the period. Finally, Signaturefd LLC grew its holdings in United Therapeutics by 4.1% in the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 35 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $555.91 on Friday. The firm has a market cap of $23.60 billion, a P/E ratio of 20.52, a P/E/G ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a 50-day simple moving average of $558.34 and a two-hundred day simple moving average of $527.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $6.63 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $554.61, for a total value of $5,268,795.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,468,914.93. The trade was a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 8,750 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $538.15, for a total value of $4,708,812.50. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,158,119.40. This trade represents a 31.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 632,718 shares of company stock valued at $356,533,651 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $619.42.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.